In our previous preclinical work, we generated IL-2/15 activated and expanded primary CAR33-NK cells that showed strong antileukemic activity against CD33+ AML cells in vitro and in a xenograft model in vivo19. This evidence concerns the gene CD33 and acute myeloid leukemia.